HARVARD MEDICAL SCHOOL | DICP
OFFICE FOR DIVERSITY INCLUSION & COMMUNITY PARTNERSHIP

is pleased to announce the

2019 - 2020 ALVIN F. POUSSAINT, MD VISITING LECTURESHIP

"Blacks in Science, Engineering and Medicine: An Imperative to Accelerate Achievement and Optimize Opportunity"

Charles R. Bridges, MD, ScD, HMS '81

Global Chief Technology Officer, Pulmonary Hypertension Therapeutic Area
Janssen Pharmaceuticals, Research and Development
Johnson & Johnson

TUESDAY, FEBRUARY 25, 2020

3:00 - 4:00 PM

Lecture | Reception to Follow

Countway Library of Medicine, Minot Room
10 Shattuck Street, Boston | Harvard Medical School

RSVP by Thursday, February 20th: www.surveymonkey.com/r/AFPlecture2020

Questions? Contact Terésa Carter via email (teresa_carter@hms.harvard.edu) **or phone** (617-432-4697).

Achieving Excellence Through Diversity - Advancing Equity and Social Justice

HARVARD MEDICAL SCHOOL | DICP
OFFICE FOR DIVERSITY INCLUSION & COMMUNITY PARTNERSHIP

2019 - 2020
ALVIN F. POUSSAINT, MD VISITING LECTURER

Charles R. Bridges, MD, ScD, HMS '81

Global Chief Technology Officer, Pulmonary Hypertension Therapeutic Area,
Janssen Pharmaceuticals, Research and Development, Johnson & Johnson

Since January of 2018, Dr. Bridges has served as the Global Chief Technology Officer, Pulmonary Hypertension Therapeutic Area, Janssen Pharmaceuticals, where he leads the development of novel therapeutic devices and the application of advanced data sciences methods to solve problems in R&D. An important goal here is to accelerate the development of novel commercially available technologies for the early diagnosis of rare diseases including pulmonary arterial hypertension. From 2015 through January 2018, he was Global Vice President, Cardiovascular Therapeutic Area Expert for Johnson & Johnson Medical Devices, serving as the worldwide scientific lead for high-profile investments and acquisitions in the Cardiovascular and Neurovascular spaces culminating in the formation of Cerenovus, Johnson and Johnson's neurovascular business in July 2017. Cerenovus achieved FDA approval for their mechanical thrombectomy platform in 2019, allowing for the reversal of the manifestations of ischemic stroke in a majority of patients. Cerenovus is now one of the fastest growing sectors in Johnson & Johnson Medical Devices. One of his first investments after joining Johnson & Johnson, a $40 million dollar equity investment in a Minnesota-based company, CVRx, led in August 2019 to the first ever FDA-approved neuromodulation device to treat heart failure. In total, he served as the scientific lead on half a billion dollars of investments in medical device technologies.

He was previously Full Professor of Surgery at the University of Pennsylvania, Chief of Cardiac Surgery at Pennsylvania Hospital; Professor and Chairman of Cardiovascular, Thoracic and Vascular Surgery at Carolina's HealthCare System, University of North Carolina. Dr. Bridges has over 180 peer-reviewed publications, 12 patents (issued and pending) with over $10M in continuous NIH-RO1 funding for nearly two decades. He was a Regular Member of the Bioengineering, Technology and Surgical Sciences Study Section of NIH from 2010-2014, and past Chairman of the Cardiovascular Committee of the American Society for Gene and Cell Therapy. He is a Co-founder of StrongHolt Therapeutics, an early stage biotechnology company developing novel gene-based therapies for heart failure and muscular dystrophy. He received an AB in Applied Physics from Harvard College *magna cum laude.* He entered Harvard Medical School at age 18, the youngest student in the entering class, receiving an MD from Harvard Medical School in the Harvard-MIT Program in Health Sciences and Technology; a Master of Science in Electrical Engineering and Computer Science and a Doctor of Science in Chemical Engineering from MIT as a Whittaker Health Sciences Fellow. He competed in the 2016 World Rubik's Cube Association US Nationals championships.